FIG 2.

CDK2 inhibition boosts HIV-1 latency establishment. Reduced CDK2 activity has been associated with an unresponsive T cell phenotype. The data presented thus test the effect of the CDK2 inhibitor roscovitine on the establishment of latent infection. (A) Effect of the CDK2 inhibitor roscovitine (10 μM) on HIV-1 susceptibility or active de novo HIV-1 infection levels on day 4 postinfection. (B) Effect of the CDK2 inhibitor roscovitine (10 μM) on maximum HIV-1 expression levels on day 4 postinfection, plotted as a function of the active infection level. (C) Establishment of reservoirs of silent infection events (day 4 p.i.) in the presence or absence of roscovitine, plotted as a function of initial active infection levels achieved in each individual culture. (D) Establishment of latent HIV-1 infection reservoirs in control and roscovitine-treated cell cultures as determined on day 14 postinfection. Each data set represents a summary of 30 paired infection cultures generated at different MOIs.